Hudson Bay Capital Management
ATOS icon

Hudson Bay Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Hudson Bay Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,082
Closed -$25.9K – 1247
2025
Q2 		$25.9K Buy
+2,082
New +$24.9K ﹤0.01% 1294
2017
Q3 		– Sell
-530
Closed -$49K – 384
2017
Q2 		$49K Buy
530
+147
+38% +$15.1K ﹤0.01% 494
2017
Q1 		$52K Buy
+383
New +$97.8K ﹤0.01% 763

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Hudson Bay Capital Management's ATOS Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 2,082 shares — an estimated $25.9K sold.

Hudson Bay Capital Management first reported a position in ATOS in Q1 2017 and held it in 3 quarters. The position peaked at $52K in Q1 2017. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Hudson Bay Capital Management reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 2,082 Atossa Therapeutics shares in Q3 2025, an estimated $25.9K.
  • Hudson Bay Capital Management first reported a position in Atossa Therapeutics in Q1 2017 and held it in 3 quarters.
  • Hudson Bay Capital Management's Atossa Therapeutics position peaked at $52K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.